Diagens Biotech Closes Over 100M yuan Series C Financing

Hangzhou-based Diagens Biotech (Chinese: 德适生物) closes over 100 million yuan series C financing led by Grand Flight Investment (Chinese: 远翼投资).

The funds will be used to develop chromosome AI diagnostic technologies and upstream reagents and consumables for assisted reproduction, as well as commercialize pre-pregnancy and reproductive health testing services across China.

Established in 2016, Diagens Biotech is a pioneer of the third generation of artificial intelligence chromosome analysis system and has launched its fertility genetic testing products in China and the EU, covering more than 290 tier 3A hospitals and providing accurate intelligent testing services for 40 million people each year.